ATOS : Summary for Atossa Genetics Inc. - Yahoo Finance

U.S. Markets closed

Atossa Genetics Inc. (ATOS)


NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
1.12+0.03 (+2.82%)
At close: 4:00PM EDT
People also watch
BIOCAPRISGNLAVEOCAPN
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Previous Close1.09
Open1.10
Bid0.98 x 500
Ask1.40 x 1000
Day's Range1.07 - 1.20
52 Week Range0.98 - 6.30
Volume126,590
Avg. Volume105,481
Market Cap4.24M
Beta1.92
PE Ratio (TTM)-0.40
EPS (TTM)N/A
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Marketwired3 days ago

    Atossa Genetics Opens Enrollment in Study of Endoxifen

    Atossa Genetics Inc. today announced that it has opened enrollment of a Phase 1 study of endoxifen, which is an active metabolite of tamoxifen, an FDA approved drug for breast cancer. The objectives of ...

  • Zacks Small Cap Research9 days ago

    ATOS: Pure Player in the Breast Care Space

    On Jan 9, 2017, Atossa (ATOS) announced that it is transferring the site of its Phase II study of fulvestrant administered with its patented microcatheters in patients with ductal carcinoma in situ or breast cancer who are scheduled for lumpectomy or mastectomy. The study was initiated at Columbia University Medical Center Breast Cancer Programs (New York) and is now being transferred to Montefiore Medical Center in New York. This move comes about as the principal investigator, Dr. Sheldon M. Feldman, M.D., has relocated to Montefiore and is now Chief, Division of Breast Surgery & Breast Surgical Oncology, Director, Breast Cancer Services, and Professor, Department of Surgery, at the Montefiore Medical Center, The University Hospital for the Albert Einstein College of Medicine, Montefiore Einstein Center for Cancer Care.

  • Marketwired2 months ago

    Atossa Genetics Provides Update on its Phase 2 Study of Fulvestrant Administered with its Microcatheter

    Atossa Genetics Inc. today announced that it is transferring the site of its Phase 2 study of fulvestrant administered with its patented microcatheters in patients with ductal carcinoma in situ or breast ...